Literature DB >> 1544938

Isolation and characterization of a chymotryptic fragment of platelet glycoprotein IIb-IIIa retaining Arg-Gly-Asp binding activity.

S C Lam1.   

Abstract

Platelet membrane glycoprotein (GP)IIb-IIIa exists as a divalent cation-dependent heterodimer which recognizes the Arg-Gly-Asp (RGD) sequence of adhesive proteins. To isolate the RGD binding domain of GPIIb-IIIa we performed proteolysis of GPIIb-IIIa with alpha-chymotrypsin. GPIIb-IIIa was bound to an affinity matrix of GRGDSPK-coupled Sepharose 4B and was then treated with chymotrypsin. After washing the unbound fragments, two discrete polypeptides of 55 and 85 kDa remained bound to the RGD affinity matrix and were specifically eluted by soluble HHLGGAKQAGDV (H12) or by GRGDSP, but not by GRGESP. Immunoblotting with subunit-specific polyclonal antibodies showed that the 55- and 85-kDa fragments were derived from GPIIb and GPIIIa, respectively. Amino-terminal sequencing and immunoblotting using site-specific antibodies indicated that these fragments contained the amino termini of their parent molecules. In the presence of 1 mM Ca2+ and 1 mM Mg2+, these two fragments were maintained as a heterodimer inasmuch as both fragments were immunoprecipitated by the polyclonal anti-GPIIIa antibodies. In contrast, chelating the divalent cations with 5 mM EDTA resulted in the lack of co-immunoprecipitation of the 55-kDa GPIIb fragment. After removal of the H12 peptide, the 55/85-kDa heterodimer bound to immobilized fibrinogen in an enzyme-linked immunosorbent assay by an RGD-dependent mechanism. These findings suggest that the RGD binding domain and structures required for heterodimer maintenance are present within the 55/85-kDa chymotryptic fragment of GPIIb-IIIa.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544938

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.

Authors:  S S Rebello; J Huang; J D Faul; B R Lucchesi
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

2.  Proteolytic degradation of the RGD-binding and non-RGD-binding conformers of human platelet integrin glycoprotein IIb/IIIa: clues for identification of regions involved in the receptor's activation.

Authors:  J J Calvete; K Mann; W Schäfer; R Fernandez-Lafuente; J M Guisán
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

Review 3.  Platelet integrin alphaIIbbeta3-ligand interactions: what can we learn from the structure?

Authors:  T Kamata; Y Takada
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

4.  Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb.

Authors:  M Poncz; S Rifat; B S Coller; P J Newman; S J Shattil; T Parrella; P Fortina; J S Bennett
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

5.  Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Authors:  James K Hennan; Ting-Ting Hong; David E Willens; Edward M Driscoll; Thierry A Giboulot; Benedict R Lucchesi
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

6.  Folding of the beta-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit.

Authors:  C Huang; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 7.  Insights into integrin-ligand binding and activation from the first crystal structure.

Authors:  Martin J Humphries
Journal:  Arthritis Res       Date:  2002-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.